Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Home
/
update
/
details

Sanofi and Orano Collaborate to Advance Next-Generation Radioligand Therapies

NextEdge Admin

18 Oct 2024

2 min 57 sec

Orano Med,radioligand therapies,precision medicine

Sanofi and Orano Med, a subsidiary of the Orano Group specializing in targeted alpha therapies for oncology, have entered into a strategic partnership to develop next-generation radioligand therapies (RLTs) focused on treating rare cancers. The collaboration aims to leverage Orano Med's expertise in alpha-emitting isotopes and Sanofi’s biopharmaceutical capabilities to accelerate the discovery, design, and clinical development of therapies under the Orano Med brand.

The new entity will focus on lead-212 (212Pb) based RLTs, which use biological vectors to deliver potent alpha-emitting radioisotopes directly to cancer cells. This approach aims to selectively damage cancer cells while minimizing harm to healthy tissue, offering a novel, precision medicine strategy for hard-to-treat cancers.

Sanofi has already secured an exclusive licensing agreement with Orano Med and RadioMedix to advance AlphaMedix™, a late-stage RLT project targeting rare cancers. This partnership aligns with Sanofi’s broader strategy to reshape its oncology pipeline, prioritizing innovative treatments for diseases with unmet medical needs, such as multiple myeloma and acute myeloid leukemia.

The collaboration reflects Orano Group’s diversification efforts, applying its nuclear technology expertise to healthcare. Orano Med has developed a global industrial platform ensuring scalable, independent access to lead-212 therapies, enhancing treatment availability worldwide.

Sanofi will invest €300 million, acquiring a 16% equity stake in the new entity, which is valued at €1.9 billion. This partnership strengthens Sanofi’s presence in oncology innovation, supporting the goals of the France 2030 initiative and the Paris Saclay Cancer Cluster.

Executives from both companies emphasized the transformative potential of the collaboration. Paul Hudson, Sanofi’s CEO, highlighted the commitment to advancing cancer care, while Nicolas Maes, CEO of Orano Group, underscored the positive societal impact of nuclear technologies beyond energy applications. Pending regulatory approvals, the partnership aims to accelerate the development of groundbreaking therapies for cancer patients worldwide.